Physician profile
David E Martin
NPI 1861043648
$4,976.22
in general payments reported to CMS, 2019-2025
41 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,469 · 2022: $810 · 2023: $668 · 2024: $650 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $917.43 | 2021 | |
| Abbvie INC. | $805.33 | 2021-2025 | |
| Exact Sciences Corporation | $349.82 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $297.52 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $290.17 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $255.97 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $192.41 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $173.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $165.51 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $142.84 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.09 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $132.77 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.31 | 2022-2024 | |
| Novo Nordisk INC | $120.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $94.12 | 2021-2024 | Trelegy Ellipta, Arexvy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.